Relapsed and Refractory Multiple Myeloma Treatment Market: By Treatment Type, By Drug Class, By Route of Administration, By Distribution Channel, and Geography  

Relapsed and Refractory Multiple Myeloma Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Chemotherapy, Radiotherapy, Stem Cell Transplantation, Others), By Drug Class (Monoclonal Antibodies, Immunomodulatory Drugs, Proteasome Inhibitors, Steroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region  

Relapsed and Refractory Multiple Myeloma Treatment Market size was valued at US$ 19.8 billion in 2023 and is poised to grow at a CAGR of 4.4% from 2024-2030. The increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases are observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe.

Moreover, a strong product pipeline for relapsed and refractory multiple myeloma treatment is expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with the European Myeloma Network (EMN) to start a phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of the market.

For instance, in January 2016, Amgen received FDA approval for a supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease is unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At the initial stage, there are no symptoms noticed with multiple myeloma,

However, in the advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may be caused by abnormal production of antibodies may cause renal problems and an increase in the thickness of blood. The disease can be considered treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.

Relapsed And Refractory Multiple Myeloma Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.4%

Largest Market

North America

Fastest Growing Market

North-America

Relapsed And Refractory Multiple Myeloma Treatment Market Dynamics

Increase in the prevalence of relapsed and refractory multiple myeloma, rise in R&D for the innovation of newer drugs, funding for the R&D activities from public and private sectors, and promising pipeline products are anticipated to fuel the relapsed and refractory multiple myeloma treatment market over the forecast years. Moreover, increase in awareness about relapsed and refractory myeloma treatment, government initiations for prevention of cancer, and launching of newer products into the market are bolster the relapsed and refractory multiple myeloma treatment market. However, stringent regulatory policies for product approval, high cost of R&D activities, and adverse effects associated with chemotherapy and radiotherapy may hinder the growth of the market over the forecast timeframe.

Relapsed And Refractory Multiple Myeloma Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 19.8 billion

Market CAGR

4.4%

By Treatment Type

  • Chemotherapy,
  • Radiotherapy,
  • Stem Cell Transplantation,
  • Others

By Drug Class

  • Monoclonal Antibodies,
  • Immunomodulatory Drugs,
  • Proteasome Inhibitors,
  • Steroids,
  • Others

By Route of Administration

  • Oral,
  • Parenteral

By Distribution Channel

  • Hospitals,
  • Hospital Pharmacies,
  • Retail Pharmacies,
  • Online Pharmacies

Key Features of the Report

  • The relapsed and refractory multiple myeloma treatment market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The global relapsed and refractory multiple myeloma treatment market size was valued at US$ 19.8 billion in 2023 and is poised to grow at a CAGR of 4.4% from 2024-2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

relapsed and refractory multiple myeloma treatment market key players are glaxosmithkline plc (u.k.), astrazeneca plc (u.k.),novartis ag (switzerland),teva pharmaceutical industries ltd. (israel)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Relapsed And Refractory Multiple Myeloma Treatment Market Introduction 
2.1.Global Relapsed And Refractory Multiple Myeloma Treatment Market  - Taxonomy
2.2.Global Relapsed And Refractory Multiple Myeloma Treatment Market  - Definitions
2.2.1.Treatment Type
2.2.2.Drug Class 
2.2.3.Route of Administration 
2.2.4.Distribution Channel 
2.2.5.Region
3.Global Relapsed And Refractory Multiple Myeloma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Relapsed And Refractory Multiple Myeloma Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Relapsed And Refractory Multiple Myeloma Treatment Market  By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Chemotherapy,
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Radiotherapy,
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Stem Cell Transplantation,
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Relapsed And Refractory Multiple Myeloma Treatment Market  By Drug Class , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Monoclonal Antibodies,
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Immunomodulatory Drugs,
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Proteasome Inhibitors,
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Steroids,
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Relapsed And Refractory Multiple Myeloma Treatment Market  By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Oral,
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parentera
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Relapsed And Refractory Multiple Myeloma Treatment Market  By Distribution Channel , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospitals,
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Hospital Pharmacies,
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Retail Pharmacies,
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Online Pharmacies
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Relapsed And Refractory Multiple Myeloma Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Chemotherapy,
10.1.2.Radiotherapy,
10.1.3.Stem Cell Transplantation,
10.1.4.Others
10.1.5.Others
10.2.  Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Monoclonal Antibodies,
10.2.2.Immunomodulatory Drugs,
10.2.3.Proteasome Inhibitors,
10.2.4.Steroids,
10.2.5.Others
10.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral,
10.3.2.Parentera
10.3.3.Others
10.4.  Distribution Channel  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals,
10.4.2.Hospital Pharmacies,
10.4.3.Retail Pharmacies,
10.4.4.Online Pharmacies
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Chemotherapy,
11.1.2.Radiotherapy,
11.1.3.Stem Cell Transplantation,
11.1.4.Others
11.1.5.Others
11.2.  Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Monoclonal Antibodies,
11.2.2.Immunomodulatory Drugs,
11.2.3.Proteasome Inhibitors,
11.2.4.Steroids,
11.2.5.Others
11.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral,
11.3.2.Parentera
11.3.3.Others
11.4.  Distribution Channel  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals,
11.4.2.Hospital Pharmacies,
11.4.3.Retail Pharmacies,
11.4.4.Online Pharmacies
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Chemotherapy,
12.1.2.Radiotherapy,
12.1.3.Stem Cell Transplantation,
12.1.4.Others
12.1.5.Others
12.2.  Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Monoclonal Antibodies,
12.2.2.Immunomodulatory Drugs,
12.2.3.Proteasome Inhibitors,
12.2.4.Steroids,
12.2.5.Others
12.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral,
12.3.2.Parentera
12.3.3.Others
12.4.  Distribution Channel  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals,
12.4.2.Hospital Pharmacies,
12.4.3.Retail Pharmacies,
12.4.4.Online Pharmacies
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Chemotherapy,
13.1.2.Radiotherapy,
13.1.3.Stem Cell Transplantation,
13.1.4.Others
13.1.5.Others
13.2.  Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Monoclonal Antibodies,
13.2.2.Immunomodulatory Drugs,
13.2.3.Proteasome Inhibitors,
13.2.4.Steroids,
13.2.5.Others
13.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral,
13.3.2.Parentera
13.3.3.Others
13.4.  Distribution Channel  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals,
13.4.2.Hospital Pharmacies,
13.4.3.Retail Pharmacies,
13.4.4.Online Pharmacies
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Chemotherapy,
14.1.2.Radiotherapy,
14.1.3.Stem Cell Transplantation,
14.1.4.Others
14.1.5.Others
14.2.  Drug Class  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Monoclonal Antibodies,
14.2.2.Immunomodulatory Drugs,
14.2.3.Proteasome Inhibitors,
14.2.4.Steroids,
14.2.5.Others
14.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral,
14.3.2.Parentera
14.3.3.Others
14.4.  Distribution Channel  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals,
14.4.2.Hospital Pharmacies,
14.4.3.Retail Pharmacies,
14.4.4.Online Pharmacies
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.GlaxoSmithKline plc (U.K.)
15.2.2.AstraZeneca plc (U.K.)
15.2.3.Novartis AG (Switzerland)
15.2.4.Teva Pharmaceutical Industries Ltd. (Israel)
15.2.5.GenMab A/S (Denmark)
15.2.6.Amgen Inc. (U.S.)
15.2.7.Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) (U.S.)
15.2.8.Unum Therapeutics (U.S.)
15.2.9.Bristol-Myers Squibb (U.S.)
15.2.10.Celgene Corporation (U.S.)
15.2.11.Bluebird Bio, Inc. (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GenMab A/S (Denmark)
  • Amgen Inc. (U.S.)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) (U.S.)
  • Unum Therapeutics (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Celgene Corporation (U.S.)
  • Bluebird Bio, Inc. (U.S.)

Related Industry Reports